Company Overview

Biomerica, Inc. is a U.S.-based biomedical technology company focused on the development, manufacturing, and commercialization of diagnostic and therapeutic products. The company primarily operates in the in vitro diagnostics and gastrointestinal disease segments, targeting early detection, monitoring, and management of chronic and acute medical conditions. Biomerica’s products are used by clinical laboratories, hospitals, and healthcare providers, with a strategic emphasis on conditions that benefit from non-invasive or minimally invasive testing.

The company’s core revenue drivers historically include diagnostic test kits for gastrointestinal and inflammatory diseases, food intolerances, and infectious conditions. Biomerica positions itself through proprietary technologies and niche diagnostic applications that are not heavily penetrated by large diagnostic companies. Founded in 1971, the company has evolved from a traditional diagnostic test manufacturer into a developer of advanced diagnostic platforms and therapeutic devices, including regulated medical devices addressing unmet clinical needs.

Business Operations

Biomerica generates revenue through the sale of diagnostic tests, medical devices, and related consumables, with operations organized around diagnostic assays and medical device development. Its portfolio includes in vitro diagnostic tests used for gastrointestinal disorders, inflammatory bowel disease, food intolerance testing, and infectious disease screening. The company also develops therapeutic and diagnostic medical devices that are subject to U.S. Food and Drug Administration (FDA) and international regulatory oversight.

Operations span both domestic and international markets, with manufacturing and research activities primarily based in the United States and distribution extending to foreign markets through subsidiaries and distributors. Biomerica operates through wholly owned subsidiaries, including Biomerica de México S.A. de C.V., which supports manufacturing and international distribution. The company maintains intellectual property covering diagnostic methodologies and device designs that support its product differentiation.

Strategic Position & Investments

Biomerica’s strategic direction emphasizes expanding its regulated diagnostic and therapeutic offerings, particularly in gastrointestinal disease and chronic condition management. A central growth initiative is the development and commercialization of its inFoods® IBS diagnostic-guided therapy, designed to personalize dietary management for irritable bowel syndrome patients. This product reflects the company’s focus on combining diagnostics with actionable treatment pathways.

The company has historically pursued organic growth rather than large-scale acquisitions, prioritizing internal research and development investments. Biomerica continues to allocate capital toward clinical studies, regulatory submissions, and intellectual property protection to support long-term commercialization. Its strategic investments are concentrated in diagnostic innovation and medical devices addressing conditions with high prevalence and limited effective diagnostic solutions.

Geographic Footprint

Biomerica is headquartered in Irvine, California, and maintains its primary executive, research, and operational functions in the United States. The company has a meaningful presence in North America and Europe, supported by direct sales efforts and distribution partnerships. International markets contribute to revenue through distributor relationships and subsidiary operations.

Beyond the U.S., Biomerica maintains manufacturing and operational capabilities in Mexico, which support cost-effective production and international supply. The company’s products are sold in multiple countries across Europe, Asia, and Latin America, reflecting a diversified geographic revenue base despite its relatively small scale compared to global diagnostics peers.

Leadership & Governance

Biomerica is led by a management team with experience in diagnostics, medical devices, and regulated healthcare markets. The company’s leadership emphasizes disciplined research and development, regulatory compliance, and targeted commercialization as core elements of its strategic vision. Governance is overseen by a board of directors responsible for corporate strategy, risk oversight, and shareholder interests.

Key executives include:

• Zackary Irani – President and Chief Executive Officer
• Charles V. Leoni – Chief Financial Officer
• John E. DeMers – Vice President of Operations
• Peter J. Casciato – Vice President of Sales and Marketing